TEVA PHARMACEUTICAL INDUSTRIES LTD
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan
Teva Pharmaceutical Industries Limited turnaround: Pivot to Growth, raised 2026 guidance, $3.7B specialty target, and more. Click for this TEVA update.
Why Teva Pharmaceutical Stock Surged This Week
Teva reported its Q2 results this week, but the stock's big gains mostly stemmed from another catalyst.
Teva Pharmaceutical Industries Limited 2026 Q2 - Results - Earnings Call Presentation
2026-07-31. The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with their 2026 Q2 earnings call.
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2026 Earnings Call Highlights: Strong Innovative ...
Teva Pharmaceutical Industries Ltd (TEVA) reports robust performance in innovative products, raising revenue guidance despite challenges in the generics segment.
Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 Earnings Call July 29, 2026 8:00 AM EDTCompany ParticipantsChristopher Stevo - Senior Vice President...
Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views
Teva Pharmaceutical Industries climbed above an important chart level Wednesday, after the company's bullish guidance overshadowed mixed second-quarter results. Teva earnings thinned to 2 cents a share after subtracting costs from an acquisition. The profit came in below the consensus estimate of 5 cents a share.
Teva Shares Climb as Revenue Beat and Innovative Drug Growth Offset Earnings Miss
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported mixed second-quarter results, with revenue exceeding Wall Street expectations while adjusted earnings fell short due to acquisition-related costs.
Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
MONTPELLIER, France, July 29, 2026--Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously.
Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
MONTPELLIER, France, July 29, 2026--Regulatory News: Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously.
Congressional Trades in $TEVA
View full $TEVA trading history →Insider Trades (Form 4)
Kalif Eliyahu Sharon
Key People
Kalif Eliyahu Sharon
EVP, Chief Financial Officer
Political Giving
$20,000 given to 7 candidates across 11 disclosed contributions (FEC Schedule A).
John Curtis
Scott H. Peters
Ashley Moody
Jake Auchincloss
August Lee Pfluger
Lori Trahan
Debbie Dingell
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro